Coagulation inhibitors in the treatment of sepsis

Bibliography

• ANGUS DC, LINDE-ZWIRBLE WT, LIDICKER J, CLERMONT G, CARCILLO J, PINSKY MR: Epidemiology of severe sepsis in the united states: analysis of incidence, outcome, and associated costs of care. Grit. Care Med. (2001) 29:1303–10.
   PubMed Web of Science ®Google Scholar
• •A recent study examining the epidemiology of sepsis in the US.
   Google Scholar
• NATANSON C, HOFFMAN WD, SUFFREDINI AF, EICHACKER PQ, DANNER RL: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann. Intern. Med. (1994) 120(9):771–783.
   PubMed Web of Science ®Google Scholar
• •A thorough discussion of the rationale for clinical trials examining anti-inflammatory therapies in sepsis.
   Google Scholar
• FREEMAN B, NATANSON C: Anti- inflammatory therapies in sepsis and septic shock. Expert Opin. Investig. Drugs. (2000) 9:1651–63.
   PubMed Web of Science ®Google Scholar
• •A recent critique of trials examining anti-inflammatory therapies in sepsis.
   Google Scholar
• FREEMAN BD, PARRILLO JE, NATANSON C: Septic shock and multiple organ failure. In: Critical Care Medicine, 2nd edition. Parrillo JE, Dellinger P (Eds.), Mosby Publishing Co., St. Louis, USA (In press).
   Google Scholar
• •A recent update on the management of patients with sepsis.
   Google Scholar
• ZENI F, FREEMAN BD, NATANSON C: Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Grit. Care Med. (1997) 25:1095–100.
   PubMed Web of Science ®Google Scholar
• CORRIGAN JJ: Heparin therapy in bacteria septicemia. j Pediam (1977) 91:695–700.
   Web of Science ®Google Scholar
• BERNARD GR, VINCENT JL, LATERRE PF et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl. I Med. (2001) 344:699–709.
   PubMed Web of Science ®Google Scholar
• •Report of a large Phase III study examining rhAPC in patients with sepsis.
   Google Scholar
• MATTHAY MA: Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties. N Engl. Med. (2001) 344:759–62.
   PubMed Web of Science ®Google Scholar
• LORENTA JA, GARCIA-FRADE LJ, LANDIN L et al.: Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest (2001) 103:1536–42.
   Web of Science ®Google Scholar
• ESMON CT: Regulation of blood coagulation. Bichem. Biophys. Acta. (2000) 1477:349–60.
   PubMed Web of Science ®Google Scholar
• CREASEY AA, CHANG AC, FEIGEN L, WUN TC, TAYLOR FB, HINSHAW LB: Tissue factor pathway inhibitor reduces mortality from Escherichia coil septic shock. Investig. (1993) 91:2850–2856.
   PubMed Web of Science ®Google Scholar
• TAYLOR FB, CHANG A, ESMON CT, D'ANGELO A, VIGANO-D'ANGELO S, BUCK KE: Protein C prevents the coagulation and lethal effects of Escherichia coil infusion in the baboon. j Clin. Invesug (1987) 79:918–25.
   PubMed Web of Science ®Google Scholar
• OPAL SM: Phylogenetic and functional relationships between coagulation and the innate immune response. Grit. Care Med. (2000) 28:S77–S80.
   PubMed Web of Science ®Google Scholar
• BERNARD G, ANGUS DC, KINASEWITZ GT: Late breaking clinical trial results: multi-center, randomized, placebo-controlled trial of recombinant human activated protein C in sepsis. 7–10. Society of Critical Care Medicine 30th Scientific and Educational Symposium. San Francisco, California, USA (10–14 February 2001).
   Google Scholar
• HARDIN R: Bleeding and Thrombosis. In: Harrison's Online. Braunwald E, Fauci AS, Isselbacher KJ et al. (Eds.) McGraw-Hill, Inc., New York, USA (2001).
   Google Scholar
• •A thorough overview of the clotting cascade.
   Google Scholar
• ESMON C: The protein C pathway. Crit. Care Med. (2000) 28:S44–S48.
   PubMed Web of Science ®Google Scholar
• GREY ST, TSUCHIDA A, HAU H, ORTHNER CL, SALEM HH, HANCOCK WW: Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes of LPS, IFN-gamma, or phorbol ester. j Irnmurrol. (1994) 153:3664–72.
   PubMed Web of Science ®Google Scholar
• HIROSE K, OKAJIMA K, TAOKA Y et al.: Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann. Surg.. (2000) 232:272–80.
   PubMed Web of Science ®Google Scholar
• HARTMENT DL, BERNARD GR, ROSENFELD BA, HELTERBRAND JD, YAN SB, FISHER CJ: Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis. Intensive Care Med. (1998) 24 (Suppl. 1):577.
   Google Scholar
• ANTI-INFECTIVE DRUG ADVISORY COMMITTEE MEETING. Center for Drug Research and Development, Gaithersburg, MD, USA (16 October 2001)
   Google Scholar
• OPAL S: Therapeutic rationale for antithrombin III in sepsis. Grit. Care Med. (2000) 28:S34–S37.
   PubMed Web of Science ®Google Scholar
• WARREN BL, EID A, SINGER P et al: High-dose antithrombin III in severe sepsis - a randomized controlled trial. ..J. Am. Med. Assoc. (2001) 286:1869–78.
   PubMed Web of Science ®Google Scholar
• •A large Phase III trial examining the role of ATIII in patients with sepsis.
   Google Scholar
• MESTERS RW, MANNUCCI PW, COPPOLA R, KELLER T, OSTERMANN H, KIENAST J: Factor VII and antithrombin III activity during sepsis and septic shock in neutropenic patients. Blood (1996) 88:854–56.
   Web of Science ®Google Scholar
• DICKNEITE G: Antithrombin III in animal models of sepsis and organ failure. Sem. Thromb. Haemost. (1998) 24:61–69.
   PubMed Web of Science ®Google Scholar
• MAMMEN EF: Antithrombin III: Its physiologic importance and role in DIC. Sem. Thromb. Haemost. (1998) 24:19–25.
   PubMed Web of Science ®Google Scholar
• FOURIER F, CHOPIN C, HUART JJ, RUNGE I, CARON C, GOUDEMAND J: Double-blind, placebo controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest (2001) 104:882–88.
   Google Scholar
• ITHRON D, HOFFMAN JM, HARTL WH, MUHLBAYER D, JOCHUM M: Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock (1997) 8:328–34.
   PubMed Web of Science ®Google Scholar
• BAUDO F, CAIMI T.M., DE CATALDO F et al.: Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. (1998) 24:336–42.
   Google Scholar
• ABRAHAM E: Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Grit. Care Med. (2000) 28:S31–S33.
   PubMed Web of Science ®Google Scholar
• CREASEY AA, REINHART K: Tissue factor pathway inhibitor activity in severe sepsis. Grit. Care Med. (2001) 29:S126–S129.
   PubMed Web of Science ®Google Scholar
• FREEMAN BD, NATANSON C: Clinical trials in sepsis and septic shock. Curr. Opin. Grit. Cam (1995) 1:349–57.
   Google Scholar
• FREEMAN BD, EICHACKER PQ, NATANSON C: The role of inflammation in sepsis and septic shock: a meta-analysis of both clinical and pre-clinical trials of anti-
   Google Scholar